Glucagon-like Peptide Drugs: Mechanisms and Health Effects [Study 219 - 226 Analysis]

Physionic

Jan 24, 2024

Episode description

*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]*
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

*HEALTH AUTONOMY [COURSE]*
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

*JOIN THE COMMUNITY*
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

*EMAIL LIST*
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

*HIRE ME FOR CONSULTING:*
Consulting: https://bit.ly/3dmUl2H

Created with Biorender
Studies, Notes, & Amendments: https://bit.ly/PhysionicGLP1A

0:00 - Introduction
1:40 - All Topics Covered
2:36 - Mechanisms of Action
24:07 - GLP1A on Health Markers
24:15 - Study 223
27:47 - Body Weight [and how to read the data]
35:37 - Heart Rate
36:35 - Blood Pressure
37:08 - Low Density Lipoproteins (LDL-Cholesterol)
38:48 - Glycated Hemoglobin (HbA1C)
45:03 - GLP1A on Mortality
45:20 - Mortality
49:09 - Side Effects
52:46 - Mid-Point Conclusions/Take Aways

********CRITIQUES, RULES, AND NOTES********

Be aware of the following rules before posting comments:
- Please do not post summaries of the video in the comments - it damages retention on the video and YouTube is less likely to promote it (these videos cost me a lot of money to produce).

Critiques of my work are welcome! Please be aware of the following notes & rules before submitting critique:

The information provided in this study analysis is limited to the subject and outcomes detailed in the study analyzed [For example: “Consuming sugar (subject) raises insulin (outcome).”] and is not meant to be an all-encompassing education on every health outcome of the subject (unless otherwise stated). I welcome all respectful critique of the study as I may have missed a key detail that you may catch; if that is the case, I will make an ‘Amendment’ to the video and credit you (thank you for making science knowledge better!). Also be aware that I receive hundreds of YouTube comments per day, so the only way your critique can be considered is if you follow the steps outlined below. Finally, YouTube auto-deletes links, so I do not see most comments with links attached.

RULES:
If your comment is rude, you will be banned.
If your comment is not about the studies/topics at hand (i.e. extending to other outcomes not discussed) or offers critique with no scientific basis, it is unlikely to receive a response.

If you can follow these rules, I will try to address your critique and if there is merit, I will add an AMENDMENT to the content in question and pin it so everyone can see it.

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

#wegovyweightloss #ozempicweightloss #glp1

Episode description

Mindsip insights from this episode:

Utilize GLP-1 agonists for safe insulin release management

GLP-1 agonists only stimulate significant insulin release when blood sugar is already elevated, which acts as a failsafe to prevent hypoglycemia.

#GLP1

#insulin

Hack brain hunger signals to control food intake

In the brain, GLP-1 agonists make neurons that inhibit food intake more likely to activate while making neurons that encourage food intake less likely to activate.

#appetite

#GLP1

Understand GLP-1 agonist drugs' longevity through enzyme resistance

GLP-1 agonist drugs are slightly modified versions of the natural hormone, making them resistant to the enzyme that normally degrades the body's own GLP-1 within minutes.

#enzyme

#GLP1

Monitor heart rate changes with GLP-1 agonists despite blood pressure reduction

While they lower blood pressure, studies show GLP-1 agonists also cause a small but statistically significant increase in resting heart rate.

#GLP1

#heart

Leverage GLP-1 agonists for gradual mortality risk reduction

The 11% relative risk reduction in mortality from GLP-1 agonists translates to a smaller ~1% absolute risk reduction over at least one year, a benefit expected to grow over time.